EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

  1. Rosenberg, J.E.
  2. Powles, T.
  3. Sonpavde, G.P.
  4. Loriot, Y.
  5. Duran, I.
  6. Lee, J.-L.
  7. Matsubara, N.
  8. Vulsteke, C.
  9. Castellano, D.
  10. Mamtani, R.
  11. Wu, C.
  12. Matsangou, M.
  13. Campbell, M.
  14. Petrylak, D.P.
Zeitschrift:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Datum der Publikation: 2023

Art: Artikel

DOI: 10.1016/J.ANNONC.2023.08.016 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus